Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

For decades, the process of drug discovery has been a prolonged, costly, and unpredictable endeavor — an effort that ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Resistance to antibiotics is increasing worldwide. This also applies to drugs that are central to the treatment of tuberculosis (TB), such as bedaquiline. An international panel of experts from 32 ...

World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...

The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).

Learn about Agentic AI and its role in enhancing decision-making in drug discovery through planned actions and verified ...

Despite significant advances in addiction science, a persistent and critical challenge remains: the vast chasm between the ...